Company: MDXG
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001376339-25-000009
Chunk: 30

Company: MIMEDX GROUP, INC.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 8
Chunk 30
---
 stockholders from continuing operations$41,998 $55,796 $(26,533)Adjustments:Dividends on previously converted Series B Preferred Stock— 6,466 6,580 Preferred share repurchase in excess of book value— 5,177 — Less: antidilutive adjustments— (5,177)(6,580)Total adjustments— 6,466 — NumeratorNet income (loss) available to common stockholders from continuing operations41,998 62,262 (26,533)Income (loss) from discontinued operations, net of tax421 (9,211)(10,244)Weighted average common shares outstanding146,979,354 116,495,810 112,909,266 Adjustments:Potential common shares (a)Previously converted Series B Preferred Stock— 27,457,905 — Restricted stock unit awards1,447,217 1,452,153 — Outstanding stock options473,015 396,779 — Performance stock unit awards149,611 137,425 — Restricted stock awards— 22,136 — Employee stock purchase plan— 254 — Total adjustments2,069,843 29,466,652 — Weighted average common shares outstanding adjusted for potential common shares149,049,197 145,962,462 112,909,266 Diluted net income (loss) per common share:Continuing operations$0.28 $0.43 $(0.24)Discontinued operations0.00 (0.06)(0.09)Diluted net income (loss) per common share$0.28 $0.37 $(0.33)(a)Weighted average common shares outstanding for the calculation of diluted net loss per common share does not include the following adjustments for potential common shares below because their effects were determined to be anti-dilutive for the periods presented:Year ended December 31,202420232022Series B Preferred Stock— 1,219,348 27,850,916 Restricted stock unit awards— — 546,883 Restricted stock awards— — 217,971 Outstanding stock options— — 65,720 Performance stock unit awards— — 5,251 Employee stock purchase plan— — 18,852 Potential common shares— 1,219,348